Original language | English (US) |
---|---|
Pages (from-to) | 829-830 |
Number of pages | 2 |
Journal | Journal of Adolescent Health |
Volume | 72 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2023 |
Funding
None. The authors of this commentary also authored written testimony on this topic which was submitted to the US Food and Drug Administration on November 3, 2022, in response to “Joint Meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” This work has not been presented at any local, regional, national or international meetings. Conflicts of interest: Drs. Lau and Hwang are Nexplanon trainers for the Merck Clinical Training Program. Drs. Otto, Klein, Santelli, Dhar, and Vyver have no relevant financial relationships or potential conflicts of interest to disclose.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Public Health, Environmental and Occupational Health
- Psychiatry and Mental health